Johnson & Johnson’s Janssen Pharmaceutical announced the submission of a supplemental new drug application to the Food and Drug Administration seeking to expand the indication of Edurant to include the treatment of HIV-1 infection in children weighing 10 kg or more. A parallel marketing authorization application has also been submitted to the European Medicines Agency in support of a type II variation and line extension for expanded pediatric use in Europe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson exec Fasolo sells 20,000 common shares
- Johnson & Johnson upgraded to Buy from Hold at Spin-Off Research
- Wall Street Goes the Irrational Route with Kenvue Stock (NYSE:KVUE)
- Johnson & Johnson price target raised to $175 from $171 at Barclays
- Johnson & Johnson Launches Exchange Offer Regarding Separation of Kenvue